Pathogenesis of polycystic ovary syndrome: Evidence for a genetically determined disorder of ovarian androgen production

References

• Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. British Medical Journal 1986; 293: 355–359
   PubMed Web of Science ®Google Scholar
• Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. New England Journal of Medicine 1989; 320: 559–565
   PubMed Web of Science ®Google Scholar
• Carey, AH, et al, Waterworth, D, Patel, K. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Molecular Genetics 1994; 3: 1873–1876
   PubMed Web of Science ®Google Scholar
• Chang, RJ, et al, Laufer, LR, Meldrum, DR. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. Journal of Clinical Endocrinology and Metabolism 1983; 56: 897–903
   PubMed Web of Science ®Google Scholar
• Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clinical Endocrinology 1989; 30: 459–470
   PubMed Web of Science ®Google Scholar
• Couzinet B, Le Strat N, Brailly S, Schaison G. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 1986; 63: 1031–1035
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Reviews 1995; 16: 322–353
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome: a changing perspective. Clinical Endocrinology 1989; 31: 87–120
   PubMed Web of Science ®Google Scholar
• Franks S. The ubiquitous polycystic ovary. Journal of Endocrinology 1991; 129: 317–319
   PubMedGoogle Scholar
• Franks S. Medical progress article: polycystic ovary syndrome. New England Journal of Medicine 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• Franks S. The 17 alpha-hydroxylase-17,20-lyase gene (CYP17) and polycystic ovary syndrome (Commentary). Clinical Endocrinology 1997; 46: 135–136
   Google Scholar
• Franks, S, et al, Gharani, N, Waterworth, D. The genetic basis of polycystic ovary syndrome. Human Reproduction 1997; 12: 2641–2648
   PubMed Web of Science ®Google Scholar
• Franks S, Gharani N, Gilling-Smith C. Polycystic ovary syndrome: evidence for a primary disorder of ovarian steroidogenesis. Journal of Steroid Biochemistry and Molecular Biology 1999; 69: 269–272
   PubMed Web of Science ®Google Scholar
• Gharani N, Waterworth DM, Williamson R, Franks S. 5′poly-morphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries (Letter). Journal of Clinical Endocrinology and Metabolism 1996; 81: 4174–4174
   PubMed Web of Science ®Google Scholar
• Gharani, N, et al, Waterworth, DM, Batty, S. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Human Molecular Genetics 1997; 6: 397–402
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 1994; 79: 1158–1165
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clinical Endocrinology 1997; 47: 93–99
   PubMed Web of Science ®Google Scholar
• Ibanez, L, et al, Hall, JE, Potau, N. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. Journal of Clinical Endocrinology and Metabolism 1996; 81: 4103–4107
   PubMed Web of Science ®Google Scholar
• Nelson VL, Legro RS, Strauss JF, III, McAllister JM. Augmented androgen production is a stable phenotype in propagated theca cells from polycystic ovaries. Molecular Endocrinology 1999; 13: 946–957
   PubMed Web of Science ®Google Scholar
• Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertility and Sterility 1990; 53: 785–791
   PubMed Web of Science ®Google Scholar
• Steingold, K, et al, De Ziegler, D, Cedars, M. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 1987; 65: 773–778
   PubMed Web of Science ®Google Scholar
• Tetchatraisak K, Conway GS, Rumsby G. Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20 lyase (CYP17) gene in hyperandrogenic states. Clinical Endocrinology 1997; 46: 131–134
   Google Scholar
• Waterworth, DM, et al, Bennett, ST, Gharani, N. Linkage and association of the insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997; 349: 986–990
   PubMed Web of Science ®Google Scholar
• White DW, Leigh A, Wilson C, Donaldson A, Franks S. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clinical Endocrinology 1995; 42: 475–481
   Google Scholar
• Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrome, A Dunaif, JR Givens, FP Haseltine, GR Merriam. Blackwell Scientific Publications, Oxford 1992; 377–384, In
   Google Scholar